Saturday, 29 October 2011

New Combined Treatment Study

This brand new combined therapy peyronie's disease study throws up some interesting results. It certainly poses questions about Verapamil, which currently has a less than positive reputation amongst patients, online at least. With traction removed from the picture the treatment regimen rather worryingly appears to have resulted in a slight loss of stretched penis length. However there was a fairly significant reduction in curvature. Perhaps the main curvature causing plaques are being reduced in size, while there is a slight continuation in loss of elasticity throughout the penis.

Adding a penis extender resulted in a more significant curvature improvement and an increase in stretched length. This is a lesson already learned, as Xiaflex injections are also thought to be much more effective in conjunction with traction therapy - a process known as modelling. It's hard to gauge the effectiveness of pentoxifylline with these factors at play. I'd tend to fall back on results from previous studies, rather than draw any pentoxifylline specific conclusions here.

I think there are still some questions over how necessary verapamil injections are, when you consider that curvature improvements of this magnitude can often be seen in men using traction or ved therapy alone (without the need for painful injections). Also with traction you often see length increases too. That was not seen here when verapamil was done without modelling via traction.

Thursday, 27 October 2011

Peyronie's Disease Clinical Research

The company have since contacted me to inform me that they did not receive the contract to carry out this research, so I have removed identifying information. In this kind of thing happens again, I won't be featuring any future research studies, as it's just a waste of peoples' time.


Dear Administrator,

Please let me introduce myself, my name is (information removed)

We regularly work with pharmaceutical companies in exploring and understanding(s) the needs and experiences of suffers of various conditions. For clarity we are not involved in drug trials.

We have just been approached by one of our regular clients to look at and understand the patient journey of Peyronie’s disease amongst diagnosed and undiagnosed sufferers. In terms of symptoms experienced, medical care, impact on their quality of life. The research findings will be used to determine the likelihood of success for a new drug that could address Peyronie’s disease.

We would be looking to conduct 10 x 1 hour telephone interviews with suffers and in return they would be incentivised with a monetary reward.

I am writing to ask if you would be willing to contact, on our behalf, your subscribers/users of your website. Any traditional method of recruitment will not be feasible due to the sensitive nature of the conditions and the fact only 1.5% of the male population is estimated to have Peyronie’s.

We can supply evidence of our accreditation and can guarantee total anonymity for anyone who is willing to talk with one of our male researchers.

(Contact information removed)